Company intelligence / Profile preview
Viramal
London, United Kingdomviramal.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Developing both prescription and non-prescription treatments for women's health conditions using transdermal and vaginal delivery systems. One product (VML-0501) is targeting endometriosis, and cannabinoids targeting pelvic inflammatory disease are in preclinical stage.
- Therapeutic areas
- Women's HealthMen's Health
- Modalities
- Small moleculesTransdermal applicationsVaginal applicationsBioadhesive vaginal gel
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Viramal.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Viramal.